FDA 510(k) submission of the AXINON^® GFR(NMR), a kidney function assay 

Exclusive license agreement with Oxford University

FDA 510(k) submission for the AXINON^®System, an NMR platform for metabolomics-based, AI-driven diagnostics

numares and Bruker Corporation sign agreement to enable advanced metabolomics-based clinical diagnostics

Numares begins strategic collaboration with Mayo Clinic Laboratories to develop new diagnostic tests

numares completes another financing round

Start of pan-European multicenter study PARASOL to evaluate metabolite constellations to detect kidney allograft rejection

Launch of AXINON^® renalTX-SCORE^®-U100: first metabolomics-based IVD test for allograft rejection diagnosis after kidney transplantation

Collaboration with Oxford University to develop a multiple sclerosis diagnostic test

1 million performed analyses

Numares completes another financing round

Launch of CE-marked IVD test AXINON^® lipoFIT^®-S100 for comprehensive NMR-based lipoprotein profiling

600,000 performed analyses

Successful completion of studies on kidney transplantation

Cooperation with a German laboratory network: commissioning a test system for lipoprotein profiling

200,000 performed analyses

Bulk order from a U.S. laboratory chain: installation of multiple test systems for lipoprotein profiling

Successful certification of numares according to EN ISO 13485: 2012 as a manufacturer of in-vitro diagnostics (IVD)

100,000 performed analyses

Certification as per EN ISO 13485:2003

Measurements in large studies, such as GRAPHIC and KORA

First patent for the determination of lipoproteins in body fluids (lipoprotein profiling)